Genome & Company joins Lilly's AI drug development platform, aiming to speed up candidate optimization
Predicted impact: Medium
Joins Lilly AI platform; small biotech, no deal value disclosed, so impact unclear.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.